ECG Screening for Atrial Fibrillation in Australian Primary Care

Atrial fibrillation is the most common sustained cardiac arrhythmia encountered in clinical practice, and its prevalence climbs steadily with age. In Australia, modelling from the Heart Foundation and the Australian Bureau of Statistics suggests hundreds of thousands of adults live with the condition, and a substantial proportion remain undiagnosed because episodes are often silent or intermittent. Untreated AF roughly doubles the risk of stroke and contributes to heart failure, cognitive decline and avoidable hospital admissions, making early detection a public health priority that sits squarely within the remit of general practice.

The general practitioner is uniquely placed to catch AF before it causes harm. Most Australians visit a GP at least once a year, and primary care clinics already perform a large share of preventive cardiovascular work, from blood pressure checks to lipid management. Pulse palpation followed by a 12-lead electrocardiogram has long been recommended in Australian guidelines, yet uptake remains patchy outside dedicated research projects. The arrival of single-lead handheld devices and improved access to mobile ECG technology has lowered the barrier, giving clinics a practical tool to embed screening into routine consultations.

This overview walks through the practical steps of implementing an ECG-based AF screening program in Australian primary care. It covers equipment choices, interpretation pathways, workflow integration, patient selection, anticoagulation referral and the system-level changes that turn a one-off audit into a sustainable service. The aim is to help practice teams move from occasional case-finding to a structured, equitable approach that reaches the patients who stand to benefit most, including those in rural and remote communities where specialist cardiology access is limited.

Why Screen for Atrial Fibrillation in General Practice

Stroke is the complication that drives most of the argument for screening. AF-related strokes tend to be more severe than those from other causes, and Australian data from the Stroke Foundation consistently show that a significant fraction of ischaemic strokes occur in patients with previously undetected AF. Because oral anticoagulation reduces stroke risk by roughly two-thirds in appropriate patients, identifying AF before the first cerebrovascular event represents one of the most cost-effective preventive interventions available to general practice.

Screening also surfaces AF in people with otherwise well-managed cardiovascular risk. A patient with controlled hypertension and a normal lipid profile may still develop paroxysmal AF, and a 30-second rhythm strip during a routine appointment can reveal it. For practices participating in the Practice Incentives Program or working under the Royal Australian College of General Practitioners standards, structured AF detection aligns neatly with quality improvement activities and continuing professional development requirements.

The evidence base has matured considerably. Large trials such as the STROKESTOP study in Sweden and the SAFER program in the United Kingdom demonstrated that systematic screening identifies new AF cases at acceptable cost, and local feasibility work in Victorian and Queensland general practices has shown that uptake improves when the test is offered opportunistically rather than as a separate visit. The challenge now is not whether to screen, but how to do it well within the constraints of Australian practice funding and time.

Choosing the Right ECG Modality for the Practice Setting

A standard 12-lead ECG remains the reference standard for AF diagnosis in Australia, and the Medicare Benefits Schedule supports its use in general practice for the investigation of suspected arrhythmia. For most clinics, a desktop 12-lead machine is the backbone of any screening workflow, with the ability to store tracings, compare with prior recordings and transmit to specialists when needed. Practices that already perform ambulatory monitoring or offer cardiac telemetry can extend their capability to confirm paroxysmal episodes.

Single-lead handheld devices have carved out a useful niche. Tools such as the AliveCor KardiaMobile and similar smartphone-connected electrodes are now familiar to many Australian GPs and are listed on the Australian Register of Therapeutic Goods. They allow a patient to record a 30-second rhythm strip in the waiting room, during a medication review or at home, and the automated algorithm provides an instant classification. While a positive single-lead reading should be confirmed on a 12-lead ECG, the handheld approach excels for opportunistic case-finding in time-pressured appointments.

For practices serving rural and remote populations, telehealth-enabled ECG kits and store-and-forward devices have transformed access. A health worker or nurse in a Western Australian or Northern Territory clinic can record a tracing and send it to a GP or cardiologist for interpretation, reducing the need for patient travel. The choice between modalities often comes down to patient demographics, practice infrastructure and local referral pathways rather than a single "best" device.

Interpreting Tracings: From Detection to Confirmation

AF on the ECG is characterised by the absence of discrete P waves and an irregularly irregular ventricular response, typically with a rate above 100 beats per minute in new presentations, though rate-controlled AF in older patients may sit lower. Practitioners should look for fibrillatory waves along the baseline, which can be coarse or fine, and confirm that the irregularity is consistent across the full tracing. A useful habit is to measure the R-R intervals with calipers or on-screen markers, as sinus rhythm with frequent ectopy can occasionally mimic the appearance of AF.

A normal or borderline single-lead recording does not exclude paroxysmal AF. If clinical suspicion remains high, for instance in a patient with cryptogenic stroke or palpitations, a 24-hour Holter monitor, a seven-day patch or an implantable loop recorder arranged through a local cardiology service may be warranted. Many Australian practices now have relationships with private Holter providers or hospital-based ambulatory monitoring units, and the Heart Foundation's clinical resources for clinicians offer practical guidance on selection.

Documentation matters. A confirmed AF tracing should be coded clearly in the medical record, with the date of first detection, the type (paroxysmal, persistent, permanent) and any relevant symptoms. This information guides future management and supports quality improvement audits. Practices that use clinical software such as Best Practice, MedicalDirector or Zedmed can create templates that prompt for these fields, making the workflow more reliable.

Integrating Screening into the GP Workflow

Time is the perennial constraint, so the most successful Australian programs weave AF detection into existing touchpoints. A 30-second pulse check followed by a single-lead ECG during a 75+ health assessment, a diabetes review or a medication review is often enough. The 45-49 year health check, Aboriginal and Torres Strait Islander health assessments and the Heart Health Check introduced through Medicare all provide natural opportunities to add a rhythm strip without lengthening the consultation significantly.

Team-based care is essential. Practice nurses can be trained to perform the initial pulse check, hand the device to the patient and flag any irregularity for the GP. Reception staff can place reminders in the appointment notes, and practice managers can track screening rates through the practice's clinical audit tool. When everyone understands their role, screening becomes part of the fabric of the clinic rather than an extra task.

Referral pathways should be mapped in advance. Practices should know which local cardiologists accept direct referrals, which emergency departments to use for haemodynamically unstable presentations, and which allied health professionals can support anticoagulation initiation. A simple flowchart on the practice intranet or in the doctor's bag can save valuable minutes. The journal's themed special collections on arrhythmia management offer useful reading for teams developing these protocols.

Patient Selection: Who Benefits Most from Opportunistic Checks

Not every patient needs a formal screening program, but certain groups are clear priorities. Adults aged 65 and over carry the highest prevalence of AF, and international guidelines, including the European Society of Cardiology recommendations, support systematic screening in this age group. The Royal Australian College of General Practitioners encourages case-finding in older patients during routine consultations, particularly those with additional risk factors such as hypertension, obesity, sleep apnoea or a history of cardiac surgery.

Patients with a recent cryptogenic stroke or transient ischaemic attack warrant extended monitoring, as up to a quarter will be found to have AF on prolonged recording. Indigenous Australians experience higher rates of rheumatic heart disease and stroke, and culturally safe screening approaches, ideally delivered through Aboriginal Community Controlled Health Organisations, are an important equity priority. People from culturally and linguistically diverse backgrounds may also benefit from translated information and interpreter-supported consultations.

Younger patients with symptoms should not be overlooked. Palpitations, unexplained fatigue, reduced exercise tolerance or a family history of AF or sudden cardiac death, where inherited arrhythmia syndromes such as those discussed in the J-wave syndromes review may be relevant, can all prompt a rhythm check. A pragmatic approach is to offer screening to anyone over 65 at least once, and to younger patients when symptoms, examination findings or risk factors raise suspicion.

Anticoagulation Decisions After a Positive Screen

A new AF diagnosis triggers a structured assessment. The CHA₂DS₂-VASc score estimates stroke risk and helps determine whether anticoagulation is indicated, while the HAS-BLED score flags bleeding risk factors that may need modification. Australian prescribing follows the PBS-listed direct oral anticoagulants, with apixaban, rivaroxaban and dabigatran generally preferred over warfarin for non-valvular AF. Shared decision-making is key, and tools such as the Heart Foundation's patient decision aids can support conversations about the benefits and risks of treatment.

Initiation does not always require a specialist. GPs in Australia can prescribe DOACs for non-valvular AF under the PBS, provided renal function, liver function and a current medication review are documented. Practices should establish a baseline process for baseline bloods, follow-up at one to four weeks, and then annual reviews that include renal function, adherence check and reassessment of bleeding risk. A clear recall system prevents patients from slipping through the cracks.

Some patients will need cardiology input. Those with valvular AF, complex congenital heart disease, very high CHA₂DS₂-VASc scores or symptoms refractory to rate control should be referred for consideration of rhythm control, ablation or advanced device therapy. Practices serving areas with limited specialist access can use the Cardiology Advice Line or telehealth services, and hospital outreach clinics in regional centres can help bridge the gap.

Building a Sustainable Local Screening Program

Sustainability comes from systems, not enthusiasm. Practices that succeed in the long term treat AF screening as a quality improvement project with a defined aim, regular data review and iterative refinement. Auditing the proportion of eligible patients screened each quarter, the proportion of positive screens confirmed on 12-lead ECG and the proportion of newly diagnosed patients started on appropriate anticoagulation gives a clear picture of progress and highlights where additional training is needed.

Partnerships strengthen the program. Local Primary Health Networks often run cardiovascular health initiatives, and aligning with their work can unlock access to shared resources, education events and bulk-billing pathways. Collaboration with local pharmacies, which now offer health checks and medication management reviews, can extend the reach of screening into the community. The Heart Foundation's "Heart Week" and similar annual campaigns provide ready-made opportunities to promote awareness.

Finally, the program should be communicated. Patients who understand why they are being asked to record a rhythm strip are far more likely to engage, and practices that share their screening data with the local community through newsletters or social media build trust and encourage attendance. The journal welcomes feedback and correspondence on implementation experiences, and readers can get in touch to share their own approaches to making AF screening a routine part of Australian general practice.